Efficacy of Tixagevimab-Cilgavimab as Immunoprophylaxis in Patients With Hematologic Cancer
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée à la COVID-19
Patients affected by hematologic malignant tumors (HMTs) remain at high risk of COVID-19 because of lower response to anti–SARS-CoV-2 vaccination. Tixagevimab and cilgavimab are fully human SARS-CoV-2–neutralizing monoclonal antibodies (mAbs) derived from B cells of patients that recovered from SARS-CoV-2. The combination of these mAbs (AZD7442) has been demonstrated to be a safe and efficient option for COVID-19 immunoprophylaxis in adults who are at higher risk of an inadequate vaccine response.Only a few series to date have evaluated the efficacy of tixagevimab-cilgavimab as primary prophylaxis in patients with various HMTs, with conflicting results. This cohort study aimed to compare the incidence and severity of COVID-19 among adult patients affected by HMTs who prophylactically received tixagevimab-cilgavimab and those who did not.
JAMA Oncology 2024